The disease itself isn't life-threatening — the damage is the depression that hits about half the men who get it, the relationships that crack, and the intercourse that quietly stops working. Real treatments exist now: one FDA-approved injection with phase-3 trial evidence, a take-home stretching device with its own randomised trial, and surgical options that straighten 80–95% of men who get to them. The whole playbook turns on showing up early. Most men don't.
The tunica albuginea is the white sleeve around the two erection chambers of your penis. Elastic in two directions, it lets the chambers fill and stiffen without tearing — every erection you've ever had relied on it. In Peyronie's, micro-tears in that sleeve heal wrong. Instead of laying down ordinary collagen and remodelling it back to smooth, the body deposits stiff, disorganised scar that doesn't stretch. The result is a tethered patch — the plaque — on one side of the shaft. When the chambers fill, the unscarred side lengthens; the plaque side doesn't. The penis bends toward the plaque, usually upward, because most plaques form on the top of the shaft.
This happens in two phases that look different from the inside. The active phase runs six to eighteen months: the plaque is soft, the surrounding tissue is inflamed, the curvature is shifting (usually worsening, sometimes stable, very rarely improving on its own), and erections often hurt. The stable phase follows: the plaque firms up — sometimes calcifies — the pain fades, and the shape locks in. The whole reason the phases matter is that they answer different treatment questions. Active is when you can still influence what happens. Stable is when you decide what to do about what's there Di Maida 2021.
Why does this happen to some men and not others? The leading explanation is a shared fibrotic tendency — the same underlying tissue-repair quirk that causes Dupuytren's contracture in the hand. Men with Dupuytren's are roughly five times more likely to develop Peyronie's; the diseases run in some families together and share gene-expression patterns Nyberg 1982. Diabetes, high blood pressure, smoking, and low testosterone all raise the odds Kadioglu 2020.
What we actually know works
The best dataset on how Peyronie's progresses without treatment comes from John Mulhall at Memorial Sloan Kettering. He followed about 246 men who showed up inside the active phase and re-evaluated them at least a year later: curvature got worse in 30–50%, stayed the same in roughly half, and improved on its own in only 3–13%. Pain had resolved in most by twelve months. Mean penile length dropped by one to two centimetres. Erectile function got worse. So the popular advice that "it'll resolve on its own" isn't what happens to the average untreated man Mulhall 2006.
The strongest treatment evidence belongs to intralesional collagenase clostridium histolyticum — branded as Xiaflex. It's a bacterial enzyme that digests the disorganised collagen of the plaque. The FDA approved it in 2013 specifically for Peyronie's — the first and only drug ever to clear that bar for this disease FDA 2013.
The second piece of solid evidence is penile traction therapy. Mayo Clinic randomised 110 men to the RestoreX device for 30 to 90 minutes a day or to nothing for three months. Curvature improved, length increased, and there were no significant adverse events. This is the first traction device to show useful results at that short a daily duration — older devices needed three to eight hours of wear, and almost no one used them consistently Ziegelmann et al. 2019. Adding traction on top of collagenase appears to make collagenase work better.
Beyond those two, the evidence thins. Intralesional interferon has one placebo-controlled trial showing roughly 13° of curvature reduction Hellstrom 2006. Intralesional verapamil failed the most rigorous placebo-controlled test it received. Vitamin E, tamoxifen, colchicine, and L-carnitine — all popular at various points — are explicitly recommended against by the American Urological Association on the basis of negative trials AUA 2015. Pentoxifylline has modest signal in a single Iranian RCT but no widespread endorsement Safarinejad 2010.
Surgery is the definitive option for the stable phase. Plication on the convex side — stitching a tuck — works best for bends under 60°, with about 90% straightening but a small obligate length loss. Plaque incision with grafting handles severe or complex deformities and preserves length, with 80–96% straightening across large series but a higher rate of new erectile dysfunction. For men with significant erection problems alongside their curvature, an inflatable penile prosthesis corrects both in one operation and is the gold standard AUA 2015.
What the year of silence costs
The most common path is the wrong path. You notice the bend; you don't want to think about it; you don't tell your partner; you definitely don't tell a doctor; a year goes by. Here's what's quietly happening during that year.
The plaque is hardening. Once it calcifies, your conservative options narrow sharply — collagenase and traction work much better on soft, evolving plaque than on stone. The curvature is settling into whatever shape it's going to keep, and in a substantial minority of men that final angle is past the point where intercourse stays mechanically possible. Your penis is getting an average of one to two centimetres shorter Mulhall 2006.
The psychological cost is accumulating in a way the field has actually measured. Validated questionnaires show clinically meaningful depression in 48% of men with Peyronie's and emotional difficulties in over 80% — and these rates do not drop with time since diagnosis. Most men do not psychologically adjust to this on their own Nelson et al. 2008. Your partner notices. Surveys of partner outcomes find about a fifth develop pain during intercourse themselves, over half report meaningful relationship strain, and a small but real fraction of couples separate over it.
The disease, treated early, is manageable. The silence is what does the damage.
What to actually do, by phase
The phase you're in determines the treatment. The rough self-test: if your curvature has been the same for at least three to six months and the pain is gone, you're in the stable phase. If it's still shifting or still painful, you're active. A urologist confirms the call with a careful exam and usually an in-office injection that produces a controlled erection — so they can measure the angle and check underlying erectile function at the same time AUA 2015.
What this costs and how to find someone who does it
The cheap end of the menu is cheap: NSAIDs, a stretching device for around $900, and oral pentoxifylline are all sub-thousand-dollar interventions. The expensive end is expensive: a full collagenase course retails in the $20,000–$35,000 range in the US, and corrective surgery or a penile prosthesis lands in the same band. The good news is that commercial insurance routinely covers collagenase and surgery once a urologist documents stable curvature meeting the FDA criteria — palpable plaque, bend between 30° and 90°. The bad news is that you need to be working with a urologist who actually treats Peyronie's regularly; collagenase requires certified prescribers, and reconstructive expertise is concentrated in a few practices per major city. Asking a general urologist how many Peyronie's cases they handle per year is a fair question to ask out loud.
What most advice gets wrong
"Vitamin E will help." It won't. Multiple placebo-controlled trials show no benefit, and the American Urological Association explicitly recommends against vitamin E, tamoxifen, colchicine, and L-carnitine on the basis of those trials AUA 2015. The supplement industry sells combination "Peyronie's formulas" anyway, mostly because the men who buy them are too embarrassed to ask anyone whether they work.
"Wait, it'll resolve on its own." Mulhall's cohort says spontaneous resolution happens in 3–13% of men. The other 87–97% stabilise or worsen Mulhall 2006.
"It's just a bend, not a real medical problem." Roughly half of men with Peyronie's are clinically depressed by validated criteria, and that rate doesn't improve with the passage of time Nelson et al. 2008. The bend is the visible part; the depression and the relationship damage are what actually hurt people.
"Nothing to do until it's bad enough for surgery." The opposite. Active-phase intervention — traction, pain control, getting comorbidities under control — is when you can still change what you end up with. Surgery is for the deformity you couldn't prevent during the year you weren't paying attention.
Where this goes wrong in practice
- The year of silence. The single most common failure: noticing the bend at month two, not seeing a urologist until month sixteen. By then the active-phase window has closed and the menu has shrunk.
- Treating the wrong phase. Collagenase injections or corrective surgery during the active phase, when the plaque is still moving, produces wasted spend and recurrent deformity. Conservative-only management for three years after the plaque obviously stabilised is the same mistake in reverse.
- Skipping the erection workup before surgery. A plication-straightened penis that can't get hard is a worse outcome than a curved one that can. The in-office injection test before surgery is how the urologist finds the men who actually need a prosthesis instead of a plication AUA 2015.
- Cutting the partner out of the decision. This disease lives in a relationship. Treatment plans made in isolation skip the cheapest, most useful intervention — having the conversation.
What it looks like when you do it right
You notice the bend in month two of the active phase. You see a urologist in month three. They confirm the phase, start NSAIDs for the pain, hand you a stretching device for the bend, and tell you to stop smoking and to bring your blood sugar under control. The pain fades by month nine. The curvature stops shifting by month fourteen.
If what's left is under 30 degrees and intercourse works fine, you're done — a permanent souvenir of a year that could have been worse. If the bend is 40 to 60 degrees and bothers you, you start collagenase: four cycles of paired injections, with home stretching three times a day between cycles. Expect roughly a third of the curvature gone by the end, with most of the bother score gone with it Gelbard et al. 2013. If you're past 60 degrees or have a real hinge effect, you go see a reconstructive urologist about surgery — about 85% of men come out straight enough for normal intercourse with grafting AUA 2015.
The realistic best case after engaged care is an intercourse-capable penis with mild residual deformity, no pain, and a relationship that came out the other side. The realistic worst case after engaged care is surgical correction at the cost of some length and a small risk of altered sensation. Both beat the silent untreated trajectory by wide margins.
Adjacent territory worth knowing about: erectile dysfunction (often comorbid; its own workup); Dupuytren's contracture (the hand version of the same fibrotic process — having it raises Peyronie's risk roughly fivefold); congenital penile curvature (present from puberty, different condition, plication-only); couples sex therapy when the relationship has taken damage; and the metabolic-syndrome cluster of diabetes, hypertension, and abnormal cholesterol that raises Peyronie's risk and shapes how it responds to treatment.
- — ED and Peyronie's travel together — the curve and the firmness problem often need addressing as a pair.
- — The real danger here isn't the bend — it's the depression that lands on about half of men. Don't tough it out alone.
- — Low testosterone tracks with Peyronie's and with the erectile trouble that comes with it, so it's worth measuring during the workup.
Substance + claimed effects
Peyronie's disease (PD) is an acquired fibrotic disorder of the tunica albuginea — the dense collagenous sheath that surrounds the corpora cavernosa of the penis. Disorganised type I and III collagen deposition forms a discrete plaque that loses elasticity and tethers the shaft, producing a curvature, indentation ("hourglass"), or shortening that becomes visible during erection Di Maida 2021. The disease has two clinically distinct phases: an acute (active) phase of 6–18 months marked by pain (in erection and sometimes flaccidity), evolving deformity, and a soft palpable plaque; and a chronic (stable) phase in which pain has largely resolved and the curvature has fixed, often with calcification of the plaque Di Maida 2021AUA 2015. This entry covers the substance (the fibrotic plaque and its phased course) and every meaningful consequence that follows: penile pain, erectile dysfunction, intercourse interference and partner-reported sexual problems, a heavy psychological burden (depression, anxiety, relationship strain), and the phase-dependent treatment trajectory — from oral and intralesional therapies and traction in the acute period, through FDA-approved intralesional collagenase, to corrective surgery (plication, plaque-incision-and-grafting, or penile prosthesis) for stable, severe disease.
Evidence by addressing question
mechanism
The dominant model is microvascular trauma → aberrant wound healing → focal fibrosis. Repeated buckling injuries during intercourse — particularly with partial erections, female-superior positions, or penile bending in cooperation with thrusting — produce delaminating shear between the inner circular and outer longitudinal layers of the tunica albuginea, with bleeding into the interlaminar space Di Maida 2021Kadioglu 2020. In genetically susceptible men this triggers a self-sustaining inflammatory cascade: reactive oxygen species drive NF-κB activation, which upregulates TGF-β1 and PDGF; fibroblasts transdifferentiate into persistent myofibroblasts that deposit disorganised type I/III collagen and lose elastin Di Maida 2021. Over months the inflammatory plaque matures into stable fibrotic scar; in 20–30% of cases it calcifies. The tethered region cannot lengthen with erection — the convex side fills normally while the concave plaque-side does not, producing the bend.
Genetic and systemic substrate. PD is now understood as a localised manifestation of a systemic fibrotic diathesis. Nyberg's 1982 pedigree analysis established autosomal-dominant inheritance in some families with HLA-B7 cross-reacting antigens and co-segregation with Dupuytren's contracture Nyberg 1982. Modern cross-sectional data confirm a 21.8% prevalence of PD in men with Dupuytren's — roughly five-fold the general-population rate — and implicate the Wnt2 locus and dysregulated Wnt signalling in susceptibility. Comorbidity associations with diabetes, hypertension, hyperlipidaemia, hypogonadism, and prior pelvic surgery are consistent with both shared vascular pathology and a generalised tissue-repair defect Kadioglu 2020.
evidence
The condition's existence and natural history are settled; treatment evidence is mixed and phase-dependent. Mulhall's prospective cohort followed 246 men presenting in the acute phase and re-evaluated them ≥12 months later: curvature worsened in 30–50%, stayed stable in 36–67%, and spontaneously improved in only 3–13%; pain resolved by 12 months in the majority; mean penile length decreased and erectile function worsened during the active phase Mulhall 2006. Spontaneous resolution is rare once a fixed plaque exists; "watchful waiting" is rational only for pain and during the months it takes the phase to declare itself Di Maida 2021.
For chronic-phase, stable curvature 30–90° without hourglass deformity, intralesional collagenase clostridium histolyticum (CCH) has the strongest evidence base. The IMPRESS I/II phase-3 RCTs (n = 832 across 64 sites, US + Australia) used up to 4 cycles of paired injections at 6-week intervals plus investigator-and-home penile modelling: mean curvature reduction of −17.0° (34%) with CCH versus −9.3° (18%) with placebo (p < 0.0001), and significant improvement in the Peyronie's Disease Questionnaire bother domain (p < 0.003) Gelbard et al. 2013. FDA-approved in December 2013, the first drug approved for PD FDA 2013. Serious adverse events (corporal rupture, large haematoma) occurred in roughly 1% — non-trivial but manageable.
Other intralesional agents carry weaker evidence. Interferon α-2b: one multi-centre placebo-controlled RCT (Hellstrom 2006, n ≈ 117) showed mean curvature reduction of ~13° vs ~4° placebo, plaque-size and pain improvements; AUA Moderate Recommendation, Grade C Hellstrom 2006AUA 2015. Verapamil: Shirazi 2009 RCT (n=80) was negative — no significant difference from saline on curvature, plaque, or pain; AUA Conditional Recommendation, Grade C; the panel notes "evidence … is weak; clinicians should carefully consider whether use of this treatment is appropriate given … other treatments that are clearly more effective" AUA 2015.
Oral therapy has consistently disappointed in adequately-controlled trials. Vitamin E, tamoxifen, colchicine, and L-carnitine are explicitly not recommended by AUA based on placebo-controlled RCT failures AUA 2015. Pentoxifylline shows modest signal — one double-blind RCT reported ~10° curvature improvement vs placebo over 6 months — but guidelines class it as off-label with limited evidence Safarinejad 2010. NSAIDs are explicitly endorsed by AUA for active-phase pain control AUA 2015.
Penile traction has moved from speculative to evidence-supported. The Mayo Clinic RestoreX RCT (NCT03389854, n=110, 3:1 randomisation, 3 months) demonstrated significant curvature reduction and length gain at 30–90 minutes/day — far less than the 3–8 hours/day older devices required — with sustained benefit at 6 and 9 months of open-label follow-up and no significant adverse events Ziegelmann et al. 2019. Modern devices typically produce 20–30% mean curvature reduction and 1.5–2.3 cm length gain with adherence > 85%. Adjunctive use with collagenase adds 5–10% curvature correction over collagenase alone.
Surgery is the definitive option for stable, severe, or function-limiting disease. Two main techniques: tunical plication on the convex side (simpler, lower morbidity, ~90% straightening, but obligate shortening proportional to curvature, best for curves < 60° without significant ED) and plaque incision/excision with grafting on the concave side (preserves length, handles complex deformities including hourglass, ~80–96% straightening — but higher rates of de novo ED, sensation loss, and prolonged recovery) AUA 2015. A 268-patient series reported 87–90% early anatomic success dropping to 83% at 36–51 months. For men with significant pre-existing ED, inflatable penile prosthesis ± manual modelling is the gold standard — corrects both curvature and erectile failure in a single procedure.
protocol
Treatment is phase-stratified.
- Acute phase (months 0–12, pain present, curvature evolving): NSAIDs for pain; address modifiable comorbidities (smoking, diabetes, hypertension); penile traction therapy (RestoreX 30–90 min/day) is the only conservative intervention with RCT support during this period; optional oral pentoxifylline 400 mg TID (off-label) or intralesional interferon α-2b (8 injections over 12 weeks) if specialist-led; no surgery during the acute phase AUA 2015.
- Stable phase (≥3–6 months unchanged curvature, no pain): If curvature is < 30° and intercourse is not impaired, no intervention is needed. For 30–90° curvature without hourglass, intralesional collagenase (Xiaflex) — up to 4 cycles of paired injections at 6-week intervals plus mandatory penile modelling and traction. For severe deformity or hourglass: surgery — plication for < 60°, plaque-incision-and-grafting for > 60° or complex, prosthesis if ED is significant Gelbard 2013AUA 2015EAU 2023.
Diagnostic workup per AUA: history (deformity, intercourse interference, pain, distress), genital exam (plaque palpation, stretched length), and in-office intracavernosal injection ± duplex Doppler ultrasound prior to any invasive intervention to objectively document curvature, vascular adequacy, and rule out occult ED AUA 2015.
contraindications
Collagenase is contraindicated in patients on chronic anticoagulation, with bleeding disorders, or with proximal plaques near the corporal-crural junction; the FDA label restricts use to palpable plaque and stable curvature 30–90° FDA 2013. Corporal rupture (≈1% of treated patients per IMPRESS) is the major procedural risk and requires emergency surgical repair Gelbard 2013. Penile traction is contraindicated during active corporal injury, recent surgery, or with un-treated active infection. Surgery is contraindicated in the active phase because plaque evolution will undo the correction.
misconceptions
(1) "It's just a bend — not a real disease." Validated PRO instruments demonstrate clinically meaningful depression in 48% of men with PD and emotional difficulties in 80%+, rates that do not decline with time since diagnosis — most men do not psychologically adapt Nelson et al. 2008. (2) "It will resolve on its own." Mulhall's cohort showed only 3–13% spontaneous improvement of curvature; the modal outcome is stabilisation or progression Mulhall 2006. (3) "Vitamin E will fix it." Multiple placebo-controlled RCTs found no benefit; AUA explicitly recommends against vitamin E, tamoxifen, colchicine, and L-carnitine AUA 2015. (4) "I should wait until it's bad enough to need surgery." Acute-phase intervention with traction and pain control measurably alters trajectory; once a calcified plaque has formed, conservative options narrow.
audience
PD is exclusively a male condition (the tunica albuginea is the substrate). Peak prevalence in the 50s–70s but cases occur from teens to octogenarians: Lindsay's Mayo cohort mean age 53 (range 19–83) Lindsay 1991; Schwarzer's 4,432-respondent German survey showed prevalence rising from 1.5% (30–39 y) to 3% (40s–50s) to 4% (60s) to 6.5% (70+) Schwarzer 2001. The Kadioglu Turkish population-based study (n=1,208) found 5.3% in men ≥30 y Kadioglu 2020. Diabetic men show ~40% PD prevalence among those presenting with ED Kadioglu 2004. Men with Dupuytren's contracture, a family history of PD, prior pelvic/radical prostatectomy surgery, or prior penile trauma carry meaningfully higher risk.
alternatives
Within PD treatment: collagenase is the FDA-approved non-surgical option for stable curvature; traction is the only conservative modality with RCT support across both phases; surgery is definitive but irreversible. Outside of PD-directed therapy, men with poor erectile function and PD often pursue PDE5 inhibitors as adjuncts (acknowledged in AUA guideline for ED management). Extracorporeal shock-wave therapy is recommended only for pain relief, not curvature, per AUA. Shock-wave for curvature is not supported by evidence.
failure-modes
(1) Delayed presentation. Embarrassment routinely delays diagnosis 12–24 months past symptom onset, by which time the plaque has stabilised and the acute-phase therapeutic window has closed. (2) Treating the wrong phase. Collagenase and surgery during the active phase risk wasted spend and recurrent deformity. Conservative-only management for years past plaque stabilisation often produces a man whose curvature, function, and confidence have progressively worsened. (3) Surgery in undertreated ED. A plication-corrected straight penis that cannot achieve rigidity is a worse outcome than a curved functional one; intracavernosal injection testing pre-op is non-optional. (4) Skipping the partner. 21% of partners develop dyspareunia, 5% report relationship disruption, 4% relationship termination; treatment-decision frameworks that ignore the partner under-count distress.
practicalities
Collagenase (Xiaflex) treatment in the US runs roughly $20,000–35,000 for a full 4-cycle course at retail; commercial insurance usually covers it with prior authorisation when AUA criteria are met. Surgery: plication $10–20k, grafting $20–35k, IPP $25–40k, all typically covered when medically indicated. Traction devices: RestoreX ~$900 out-of-pocket. Visits: minimum 8 specialist visits over ~12 months for a collagenase course; weekly to monthly for 12 weeks for interferon. Modelling at home: 3×/day between cycles in the IMPRESS protocol — adherence matters. Geographic access: collagenase requires certified prescribers; concentrated in major urology practices.
history
Described by François Gigot de la Peyronie, surgeon to Louis XV, in 1743 — making it one of the oldest formally described urologic conditions. Therapeutic history is a chronicle of low-evidence enthusiasm: heavy metals, radiation, hyperbaric oxygen, vitamin E, tamoxifen, colchicine — all popular in their era, all subsequently shown ineffective or unsafe. Intralesional verapamil (1990s) and interferon (2000s) were genuine advances but modest in effect size. FDA approval of collagenase in December 2013 — the first drug ever approved specifically for PD — represented the field's first high-evidence pharmacological treatment FDA 2013.
stakes
Untreated active-phase PD predictably leads to: pain through the first year; curvature stabilisation that may or may not allow intercourse; mean length loss of 1–2 cm Mulhall 2006; new-onset erectile dysfunction in a substantial fraction; and a high probability of sustained psychological burden — clinically meaningful depression in roughly half of men, persistent across years post-diagnosis Nelson et al. 2008. Relationship disruption is documented in >50% of couples; partner sexual dissatisfaction in ~21%; relationship termination in 3–4%. Intercourse becomes mechanically impossible at curvatures > 60° or with hourglass deformity in a meaningful minority. The silent path — embarrassment, delay, isolation — is the worst path.
payoff
Recognising the disease early, getting onto traction therapy and pain control during the acute phase, and arriving at the stable phase with a tractable curvature opens the full menu of effective options: collagenase reliably trims roughly a third of the bend Gelbard et al. 2013; surgery straightens 80–95% of patients; depression and bother scores improve measurably alongside curvature improvements. The realistic best case is a functional, intercourse-capable penis with mild residual deformity and resolved pain; the realistic worst case after appropriate care is surgical correction at the cost of some length and sensation. Both beat the untreated trajectory by wide margins.
out-of-scope
Pointers, not justifications: erectile dysfunction more broadly, congenital penile curvature (different condition, plication-only), Dupuytren's contracture (shared fibrotic diathesis), pelvic-floor physical therapy, sex-therapy adjuncts for couples adjusting to deformity, diabetes and metabolic-syndrome management (modifies PD risk).
The credibility range
Optimist case
PD is a now-tractable condition for the modern andrology patient. We have a confirmed pathophysiology (microvascular injury + fibrotic diathesis), a validated phase model that tells clinicians when to intervene with what, an FDA-approved intralesional drug with phase-3 RCT data showing meaningful efficacy Gelbard 2013, an RCT-supported traction device usable at home Ziegelmann et al. 2019, surgical techniques with 80–95% straightening rates, and a clinical-guideline framework that pulls it all together AUA 2015. Combination protocols (collagenase + traction) produce additive benefit. The remaining gap is access and timely diagnosis — embarrassment-driven delay, not treatment efficacy.
Skeptic case
The evidence is thinner than the field's confidence suggests. The signature trial (IMPRESS) reports a mean curvature improvement of 17° from a baseline near 50° — clinically real but modest, and the placebo arm itself improved 9° (penile modelling alone does work, perhaps because the active phase resolves on its own in some patients). Phase-3 follow-up was 52 weeks; long-term durability remains poorly characterised. Verapamil, interferon, and most oral therapies have evidence ratings of Grade C at best AUA 2015. Patient-selection effects are large — IMPRESS excluded men with hourglass deformity, calcified plaques, dorsal curvature with hinge effect — populations who are common in real practice. Costs are substantial and a high proportion of "responders" still proceed to surgery. Psychological burden persists even after successful physical treatment Nelson et al. 2008.
Author's call
PD is one of the better-characterised andrology conditions, but it sits at evidence level 3 (clear from the modal addressing-question subsection above): the disease and its phases are established; a single high-evidence intralesional therapy exists; everything else carries Grade C or weaker. The phase-stratified protocol from AUA 2015 is the right operational frame. Acute-phase patients should be on traction and pain control; stable-phase patients with intercourse-limiting curvature deserve a real discussion of collagenase vs surgery, with realistic effect-size disclosure. The single biggest lever for population outcomes is reducing diagnostic delay — most men present after the acute window has closed.
Stakeholder + incentive map
- Endo Pharmaceuticals (collagenase / Xiaflex) — commercial incentive to position CCH as first-line; phase-3 trials industry-sponsored; collagenase withdrawn from European market in 2020 (commercial, not efficacy reasons) constraining the menu there.
- RestoreX / PathRight Medical — traction device manufacturer; provided devices for the Mayo RCT at no cost, internal Mayo funds for trial — modest conflict, peer-reviewed publication.
- AUA / EAU / ISSM / SMSNA — guideline-issuing bodies; broadly aligned on phase-stratification and treatment menu; AUA has been the most active in producing updated, evidence-graded recommendations.
- Reconstructive urologists — surgical volume incentive; tend toward surgery-favouring framings; high real-world expertise.
- Online communities — large active forums (Reddit r/PeyroniesSupport, PeyroniesForum) where men trade protocol details, traction-device tips, and surgical comparisons; useful felt-experience signal; high anxiety baseline; supplement-vendor marketing intrusion.
- Compounded-supplement vendors — vitamin E + L-arginine + collagen formulations marketed as "Peyronie's treatments" despite negative RCTs and AUA recommendations against; commercial incentive against evidence.
Population variability
- Age: prevalence rises monotonically from ~1.5% in 30s to 6.5% in 70s Schwarzer 2001. Younger men (< 40) tend to have more aggressive curvature progression and worse psychological response.
- Comorbidity load: diabetes (40% of PD-ED presenters), hypertension, dyslipidaemia, hypogonadism, and smoking are independently associated with both prevalence and severity Kadioglu 2004Kadioglu 2020.
- Fibrotic diathesis: men with Dupuytren's contracture, plantar fibromatosis (Ledderhose), or knuckle pads carry a recognised "fibrotic phenotype" with higher PD risk and possibly worse progression Nyberg 1982.
- Post-prostatectomy: an under-appreciated population with elevated PD incidence, complicated by superimposed ED — traction therapy has independent RCT data in this group.
- Curvature direction matters: dorsal curvature is most common (~70%); ventral curvature with hinge effect or hourglass deformity is more functionally disabling and harder to treat conservatively.
Knowledge gaps
- Long-term (5–10 year) durability of collagenase-induced curvature improvement; do plaques re-fibrose?
- Whether early intervention during the acute phase changes the natural history — most acute-phase trials are small.
- Effective combination protocols (e.g., traction + intralesional + oral antifibrotic) vs each modality alone — comparative RCTs are sparse.
- Mechanism by which psychological burden persists post-physical-correction; whether structured psychological intervention added to medical care reduces the depression burden.
- Causal validation of the microvascular-trauma model in humans (imaging studies of initial injury are technically difficult); genetic markers that would identify the high-risk diathesis prospectively.
- Whether the placebo improvement seen in IMPRESS reflects penile modelling itself (a usable intervention) versus regression to mean.
Coverage vs brief. Brief named erectile function, pain, sexual function, psychological wellbeing, and treatment trajectory across stages. All covered: ED in mechanism + protocol + failure-modes; pain in stakes + protocol; sexual function in stakes + payoff; psychological wellbeing in stakes + misconceptions (and is the load-bearing dimension in meta at score 4); phased treatment trajectory in protocol + payoff.
Rating calls.
- Mood at 4, not 5. Depression rates of 48% and the relationship damage easily clear the 4 threshold (substantial effect on inner wellbeing or anxiety/depression). I held it at 4 because recognising and treating PD does not deliver a transformative psychiatric intervention on its own — psychological burden persists in a meaningful fraction even after successful physical correction (Nelson et al. 2008). 5 would overclaim.
- Cost at 3, not 4. Collagenase and surgery both run $20–40k retail, which is a 4-tier number; insurance routinely covers them when medically indicated, and many men pay $0–2k out-of-pocket. Held at 3 to reflect the median treated patient rather than the worst-case uninsured one.
- Effort at 3, not 4. Traction at 30–90 min/day for months and collagenase home-modelling three times a day are substantial but not lifestyle-dominating. Surgery is a one-shot. Average across treatment paths lands at 3.
- Evidence at 3. Disease and natural history are settled. IMPRESS is a strong RCT for one treatment; RestoreX is a real RCT for traction; everything else is Grade C. The catalogue's anchor for 4 is "one good RCT or consistent observational data, clinical community broadly aligned" — the field aligns broadly on the framework but not on individual non-CCH treatments. 3 is the honest call.
- Action: respond, not decide. Decide was a close second because treatment selection genuinely involves clinician-led tradeoffs. I went with respond because the entry's trigger is symptom onset; the framework tells the reader what to do when this happens, and decision-making is the substrate of the protocol section rather than the entry's primary action.
Audience scoping. Gender locked to male (anatomical substrate). Age band left open: peak prevalence is 50–70, but a young man with new curvature is the highest-leverage reader (acute-phase window still open) and case reports run from teens. Restricting ages would shrink reach for no truthfulness gain.
Contraindications field left empty. Specific treatment contraindications (collagenase + blood thinners; surgery in active phase) are surfaced in the protocol warning callout. The entry as awareness/recognition isn't unsafe for any vocabulary token.
Separate-entry candidates / future links.
dupuytren-contracture— flagged inrelated; shared fibrotic diathesis warrants its own entry, and a cross-link will sharpen both.erectile-dysfunction— flagged inrelated; deep comorbidity overlap with PD and a separate workup. Cross-link when it exists.penile-prosthesis— distinct intervention with its own decision framework; worth its own entry rather than living inside a couple of sentences here.penile-traction-therapy— also used post-prostatectomy and for cosmetic length; potentially a standalone entry.
Excluded from the article. Detailed surgical comparison tables (plication vs grafting per-technique outcomes) — too technical for the friend-test bar; the dossier covers it for reviewers. Intralesional verapamil dosing and protocols — RCT-negative, no reason to teach a protocol the AUA explicitly soft-rejects. Extracorporeal shock-wave for curvature — mentioned only to recommend against. Sex-therapy and couples-counselling protocols — flagged as adjacent in out-of-scope but not detailed; would need its own entry.
Partner-impact framing. The entry is male-audience but the partner appears in stakes and failure-modes. This is deliberate — the strongest behaviour-changing lever (talking to the partner) lives in the relationship, and erasing the partner to keep the audience pure would have weakened the stakes section.
Peyronie's Disease
Validated PRO instruments show clinically meaningful depression in 48% of men with PD and emotional difficulties in 80%+, stable across years since diagnosis (Nelson et al. 2008). Relationship disruption is reported in >50% of couples. Recognition plus phase-appropriate treatment (collagenase, surgery, prosthesis) measurably reduces PDQ bother scores and the depression burden.
Pain in the active phase typically resolves by 12 months, and appropriate phase-stratified care preserves intercourse function in the majority of treated men. Untreated, curvature stabilises or progresses to functionally limiting deformity in the majority of cases (Mulhall 2006), with new-onset erectile dysfunction in a substantial fraction.
Collagenase (Xiaflex) full course retails ~$20–35k; reconstructive surgery $20–40k; penile prosthesis $25–40k. Traction devices ~$900 and oral therapies are sub-hundred. Most medically-indicated treatments are insurance-covered in the US with prior authorisation; the burden lands on the uninsured and those pursuing cash-pay specialty care.
Penile traction protocols require 30–90 minutes daily for months (Ziegelmann 2019); collagenase regimens run up to four 6-week injection cycles with home penile modelling three times per day between cycles (Gelbard 2013). Surgery is a one-shot but with weeks of recovery and intercourse abstinence.
Disease and natural history are settled (Mulhall 2006, Schwarzer 2001). Intralesional collagenase is anchored by two phase-3 RCTs in 832 men (Gelbard 2013) and is FDA-approved. RestoreX traction is RCT-supported (Ziegelmann 2019). Most other intralesional agents, oral therapies, and adjuncts sit at AUA Grade C with mixed RCT evidence (AUA 2015).